US EditionMerck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib
- On April 1, 2025, Beijing Time, Abbisko Therapeutics announced that Merck has exercised its option for global commercialization rights to pimicotinib .
- In December 2023, Abbisko Therapeutics and Merck entered into an exclusive licensing agreement, referred to as "the Agreement", concerning pimicotinib, a CSF-1R inhibitor.
- Pimicotinib demonstrated positive topline results in the Global Phase III MANEUVER Study for tenosynovial giant cell tumor with an objective response rate of 54.0% at Week 25 compared to 3.2% for placebo , and was generally well-tolerated.
- The option exercise fee is USD85.0 million, adding to the USD70.0 million upfront payment Abbisko received in February 2024, with potential for up to USD605.5 million in total payments plus double-digit royalties.
- Merck's decision to exercise the option deepens its collaboration with Abbisko, reflecting a shared commitment to advancing new treatment options in rare oncology and delivering a potentially best-in-class therapy to patients with TGCT, who currently have limited treatment options.
Insights by Ground AI
Does this summary seem wrong?
25 Articles
25 Articles
All
Left
3
Center
8
Right
4
Altavista Journal+23 Reposted by 23 other sources
Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib
SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of USD85.0 million, under the…
·Altavista, United States
Read Full Article
Coverage Details
Total News Sources25
Leaning Left3Leaning Right4Center8Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 20%
C 53%
R 27%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
